Tesamorelin is a synthetic research peptide and a stabilized analogue of growth hormone-releasing hormone (GHRH), designed to selectively activate the GHRH receptor and stimulate endogenous growth hormone secretion in experimental models. Preclinical and clinical research has focused on its role in modulating somatotropic signaling, lipid metabolism, and the regulation of visceral adipose tissue via cAMP-dependent pituitary pathways. Tesamorelin is used in research studies that examine the dynamics of the hypothalamic-pituitary axis, metabolic signaling, neuroendocrine regulation, and growth hormone-mediated tissue effects.